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Abstract: Oncostatin M (OSM) is a cytokine belonging to the gp130 family, whose members
serve pleiotropic functions. However, several actions of OSM are unique from those of other
gp130 cytokines, and these actions may have critical roles in inflammatory mechanisms
influencing several metabolic and biological functions of insulin-sensitive tissues. In this
review, the actions of OSM in adipose tissue and liver are discussed, with an emphasis on
lipid metabolism.
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1. gp130 Cytokines
The interleukin (IL)-6 family is a group of structurally similar cytokines that includes IL-6, IL-11,
IL-27, leukemia inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor, cardiotrophin-1
(CT-1), novel neurotrophin-1/B cell stimulating factor-3 or cardiotrophin-like cytokine, and neuropoietin
(reviewed in [1]). Since all members of this cytokine family require glycoprotein 130 (gp130) as a
common signal transducer in their receptor complexes, the IL-6 family members are referred to as the
gp130 cytokines. The principal signal transduction pathway facilitating the response to gp130 cytokines
is the Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) pathway, which
primarily activates STAT3.
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The gp130 cytokines regulate a diverse array of biological processes, including hematopoiesis,
immune responses, inflammation, stem cell potency, cardiovascular pathophysiology, and neuronal
survival (reviewed in [2]). Circulating levels of many gp130 cytokines, namely IL-6, CT-1, LIF, and
OSM, have been observed in humans [3–9]. Though the actions of this cytokine family in modulating
lipid metabolism and fat cell function have not been fully elucidated, some gp130 cytokines, including
CNTF and IL-6, have been targeted as potential therapeutic strategies in the treatment of obesity [10].
Some gp130 cytokines can exert profound effects on adipose tissue (AT), body weight, and glucose and
lipid metabolism in rodents and humans [11–20]. AT and its primary constituents, adipocytes, are highly
responsive to gp130 cytokines [19,21–25]; however, the effects of these cytokines in regulating lipid
accumulation have not been fully characterized.
2. Oncostatin M
OSM is a gp130 cytokine that shares substantial sequence identity with LIF [26]. LIF and OSM
evolved by gene duplication relatively recently [27]. Though originally identified for its ability to inhibit
cancer growth in humans [28], OSM can modulate a variety of biological processes. However, unlike
other gp130 cytokines, OSM has its own specific receptor, OSMR, that heterodimerizes with gp130 [29]
and mediates the majority of OSM effects. There is some evidence that OSM is the only gp130 cytokine
with the unique ability to signal through two distinct receptor units—the gp130/LIF receptor (LIFR)
complex [30] and the gp130/OSMR complex [29]. However, other studies have shown that murine
OSM only signals through the gp130/OSMR receptor complex [31,32]. These results have been
confirmed, and since there is some receptor cross-talk among gp130 cytokines [33], it is critical to note
that that mouse OSM only results in the tyrosine phosphorylation of gp130 and OSMR and does not
signal via LIFR [31–33]. Similarly, human OSM only activates gp130 and OSMR and not LIFR in
human adipocytes.
OSM can regulate inflammatory responses and is produced by activated T cells and
macrophages [28,34,35]. In murine models of chronic inflammatory diseases, such as rheumatoid
arthritis (RA) and multiple sclerosis, OSM has been shown to suppress inflammation [36]. Conversely,
elevated OSM expression is found in a variety of inflammatory diseases in humans, including RA and
atherosclerosis [37–39]. OSM has important roles in liver development and regeneration [40–42],
hepatic insulin resistance and steatosis [43], inflammation [44], and cardiomyocyte dedifferentiation and
remodeling [45]. Nevertheless, the actions of OSM on metabolic functions have not been fully elucidated
and recent studies suggest pro-inflammatory roles of OSM on adipocytes [46]. Importantly, AT in vivo
is highly responsive to OSM as compared to other insulin-sensitive tissues [33]. Mice given acute (20 min)
OSM injections had robust STAT phosphorylation in two white AT depots (epididymal and
retroperitoneal). The response to OSM in brown AT, liver, and skeletal muscle was minimal compared
to white AT [33]. It is also known that OSM can inhibit adipocyte differentiation in vitro [25,47]. Several
gp130 cytokines can have differential effects on both adipogenesis and insulin-stimulated glucose uptake
in vitro and in vivo [19,21–25]. However, the actions of OSM on insulin signaling, lipid metabolism and
glucose uptake require further investigation.
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3. OSM Modulation of Adipocyte Differentiation
There are many hormones that affect lipid storage by promoting and/or inhibiting adipocyte
development (reviewed in [48]). In the recent past, it was speculated that inhibitors of adipocyte
development may act as suitable anti-obesity therapeutics by attenuating fat cell mass. In obesity, AT
expansion can be accompanied by adipocyte dysfunction and alterations in adipokine secretion that can
contribute to the development of metabolic diseases (reviewed in [49]). Cytokines that inhibit
adipogenesis, such as tumor necrosis factor alpha and interferon gamma, tend to have metabolically
unfavorable effects such as the induction of insulin resistance (reviewed in [50]). These cytokines and
other adipocyte differentiation inhibitors can block fat cell expansion, a condition that has been
recognized as a causative factor for insulin resistance for over a decade [51].
Several groups have demonstrated that OSM inhibits adipocyte development in vitro [25,33]. Also
mice that have a global deletion of OSMR have increased adiposity [52], supporting the notion that
OSM acts to block adipogenesis and that lack of OSM signaling leads to increased AT expansion. There
is also evidence to suggest that OSM treatment of mice results in weight loss accompanied by decreased
fat mass and, therefore, less lipid accumulation [52,53]. However, the OSM doses used in these studies
were very high (12.5 ng/g body weight, administered twice daily) [52,53] and may have caused illness
in the animals. In humans with diseases such as cancer and periodontitis, OSM is present in circulation
at values ranging from 20 pg/mL to 100 pg/mL [54,55], while OSM is minimally detectable in healthy
individuals. Therefore, the doses used in these animal studies are at least three to four orders of
magnitude above the highest reported circulating OSM value for a human, and the impact of these high
doses is likely much greater in mice. Nonetheless, these independent studies strongly suggest that OSM
inhibits adipocyte development both in vitro and in vivo.
4. OSM is an Adipokine
An important AT function includes the production and secretion of factors (adipokines) that mediate
whole body metabolism. Several adipokines can modulate physiological systems, as well as pathological
conditions such as insulin resistance and inflammation (reviewed in [56]). AT is a well-known source
of two gp130 cytokines, IL-6 [57,58] and CT-1 [7]. Previous studies have shown that murine adipocytes
in vitro and white AT in vivo are responsive to OSM [33]. Hence, we examined OSM expression in
mouse and human AT. We demonstrated that OSM mRNA and protein levels were elevated in AT of
both ob/ob mice and high-fat diet (HFD)-fed B6 mice [46]; these rodent models are both used to study
obesity and type 2 diabetes (T2DM). An analysis of human subcutaneous AT revealed that OSM levels
correlated with body mass index (BMI), with substantial inductions of OSM protein levels seen in AT
from subjects with BMIs of 40 or above [46]. These were the first studies to demonstrate that OSM
mRNA and protein levels are elevated in obese/T2DM mice and humans. Interestingly, OSM is present
in non-adipocyte cells of human AT. In mice, OSM is present in both CD11c+ and CD11c macrophages
that are F4/80+ and are found in AT of wild type and ob/ob mice [46]. OSMR is highly expressed in
adipocytes, and OSM treatment of adipocytes induces IL-6 and PAI-1 expression [46,59]. In addition to
positively correlating with body weight, increased OSM levels also positively correlate with insulin
levels and are negatively associated with glucose disposal rates in humans [46]. Collectively, our data
suggest that AT-derived OSM acts on preadipocytes and adipocytes (see Figure 1) and may modulate
glucose and lipid metabolism and contribute to metabolic disease states.
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Figure 1. Oncostatin M (OSM) is produced in adipose tissue and liver immune cells and acts
in a paracrine manner in these insulin-sensitive tissues. OSM is produced in T cells and
macrophages that are found in adipose tissue and are elevated in conditions of obesity/insulin
resistance. OSM receptors are present on preadipocytes and adipocytes, but not macrophages. It
is well-known that OSM inhibits adipocyte differentiation. In addition, OSM acts on adipocytes
to induce IL-6 and PAI-1 production. These abilities of OSM suggest that blocking OSM
receptor activity in preadipocytes and adipocytes may be metabolically beneficial. In liver,
OSM is produced in Kupffer cells (resident macrophages) and acts in a paracrine manner on
hepatocytes to decrease insulin sensitivity and increase liver lipid accumulation.
5. Hepatic Effects of OSM
The hepatic functions of OSM are diverse and well documented [40–43,60–64]. A few years after the
discovery of human OSM, its role as a potent inducer of the acute phase response in rat primary
hepatocytes was identified [64]. Similar effects of mouse OSM were subsequently reported [65].
Evidence also suggests that hepcidin, a protein produced by the liver and a key regulator of iron metabolism,
is an OSM target [60] and that OSM may play a role in anemia-associated disorders [60,62].
Interestingly, critical roles for OSM in fetal hepatic cell differentiation and hematopoiesis have also been
reported [42]. Liver regeneration capability is impaired in OSMR knockout mice [41], and OSM has
been shown to stimulate rat oval cell differentiation into hepatocytes, suggesting a role for OSM in the
regenerative ability of hepatic tissue [63].
Further, OSM was found to up regulate the LDL receptor and rapidly increase phospholipid and
diacylglycerol metabolism in HepG2 cells, highlighting a possible role for OSM in hepatic lipid
metabolism [61]. Further support of this potential role is demonstrated in Kupffer cells, whose OSM
production can inhibit the expression of several key enzymes of hepatic lipid metabolism [43]. Kupffer
cell OSM has also been shown to attenuate insulin-stimulated Akt phosphorylation and glucokinase
induction in hepatocytes, and is also up regulated in non-alcoholic steatohepatitis [43]. These results
suggest overall that OSM produced by Kupffer cells may have a paracrine effect on hepatocytes to cause
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insulin resistance and lipid accumulation, and that these effects may contribute to systemic insulin
resistance and metabolic syndrome. These results are consistent with observations of OSM being
produced in AT macrophages (ATMs) and modulating pro-inflammatory genes in adipocytes (see Figure 1).
6. Metabolic Studies in OSMR Knockout Mice
Two recent studies from Komori and colleagues in OSMR-deficient mice suggest a metabolically
protective role for OSM signaling [52,53]. However, it is necessary to interpret these studies with
caution, as they were conducted in global OSMR KO mice. Since OSMR plays a known role in
hematopoiesis and other biological functions beginning prior to birth [42], it is possible that many of the
effects seen in these studies were due to other developmental and/or systemic alterations.
Results from the first study indicate that OSMR KO mice exhibit AT inflammation, insulin resistance,
increased hepatic and serum lipid concentrations, and beta cell hyperplasia on normal chow diet [52].
These results suggest that OSM signaling plays an important role in lipid handling in AT and liver. Also,
wild-type B6 mice were injected with OSM twice daily for one week and glucose tolerance, insulin
sensitivity, and ATM populations assessed. OSM treatment decreased the total number of F4/80+ cells,
but the percentage of pro-inflammatory M1 ATMs was lower while the percentage of anti-inflammatory
M2 ATMs increased [52]. Improvements in glucose tolerance and insulin sensitivity in OSM-treated
mice were also observed, suggesting that possible metabolically favorable improvements likely have
beneficial effects on lipid metabolism. However, it is difficult to assess whether the mice were healthy
during the injections, as no food intake or body weight data were reported [52]. Possible decreases in
appetite and body weight, resulting from the supraphysiological doses of OSM used in these experiments,
could account for the alterations observed in glucose metabolism.
In a follow-up study by the same group, ob/ob mice were injected with OSM twice daily for one
week [53]. Significant improvements in insulin sensitivity, glucose tolerance, AT inflammation, and
hepatic steatosis were seen in OSM-injected mice. However, body weight also significantly decreased
in the OSM-injected mice, and this may partially account for the improvements. Additionally, OSMR
KO mice were fed a HFD for 8 weeks and exhibited greater body weight and food intake than control
mice. Further, the insulin resistance, AT inflammation, and hepatic steatosis observed were more severe
in the obese KO mice than in the control mice [53]. The severity of these effects was not resolved when
OSMR KO mice were pair-fed with control mice, suggesting that the effects were independent of body
weight gain. AT inflammation, ATM accumulation, and ATM polarization to the M1 phenotype was
markedly increased in KO mice as early as 2 weeks on HFD. Hepatic lipid metabolism was more closely
evaluated in this study, and OSMR KO mice demonstrated more severe liver lipid accumulation as
determined by histology, tissue triglyceride quantification, and tissue total cholesterol quantification [53].
The OSMR KO mice also exhibited increased hepatic expression of fatty acid synthesis genes, which
was not affected by pair feeding. These results suggest that altered lipid metabolism in the OSMR KO
mice may be responsible, in part, for the insulin resistance reported in these animals.
While the results from both studies do support a putative role for OSM signaling in lipid metabolism
in both AT and liver, the use of global OSMR KO mice makes it difficult to determine cause and effect
and to assess whether their phenotype is related to developmental factors. Future studies should be
conducted on tissue-specific or tissue-specific inducible OSMR KO mice to address current confounding
data and the developmental and systemic effects of OSM.
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7. Summary and Future Directions
Our understanding of OSM and its ability to modulate lipid metabolism is rudimentary. To date, there
is confounding data on whether OSM induces metabolically beneficial [52,53] or metabolically
detrimental effects [43,46,66]. Since OSM is highly produced in conditions of excess lipid storage as
judged by adiposity [46], we predict that OSM will have profound effects on glucose and lipid metabolism
(see Figure 1). As indicated above, it will be essential to examine tissue-specific manipulation of both
OSM and OSMR to determine the primary tissue sources of OSM as well as the action of this cytokine
on tissues involved in lipid metabolism.
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